阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

休市中 09-04 16:00:00 EDT

162.70

-2.07

-1.26%

盘后163.00

+0.30+0.18%

19:57 EDT

最高163.78	最低161.13	成交量307.33万
今开162.82	昨收164.77	日振幅1.61%
总市值2,523亿	流通市值2,439亿	总股本15.51亿
成交额4.99亿	换手率0.21%	流通股本14.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":162.7,"timestamp":1788552000000,"preClose":164.77,"halted":0,"volume":3073349,"hourTrading":{"tag":"盘后","latestPrice":163,"preClose":162.7,"latestTime":"19:57 EDT","volume":839985,"amount":136665225.0918,"timestamp":1788566232929,"change":0.3,"changeRate":0.001844,"amplitude":0.009096},"delay":0,"changeRate":-0.012562966559446631,"floatShares":1498932637,"shares":1551000000,"eps":6.679974,"marketStatus":"休市中","change":-2.07,"latestTime":"09-04 16:00:00 EDT","open":162.82,"high":163.78,"low":161.13,"amount":499094666.84559995,"amplitude":0.016083,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.679974,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NYSE","adjPreClose":164.77,"dividendRate":0.019444,"preHourTrading":{"tag":"盘前","latestPrice":162.86,"preClose":164.77,"latestTime":"09:29 EDT","volume":30584,"amount":4998270.024239999,"timestamp":1788528599499,"change":-1.91,"changeRate":-0.011592,"amplitude":0.014543},"postHourTrading":{"tag":"盘后","latestPrice":163,"preClose":162.7,"latestTime":"19:57 EDT","volume":839985,"amount":136665225.0918,"timestamp":1788566232929,"change":0.3,"changeRate":0.001844,"amplitude":0.009096},"volumeRatio":1.0765374277756994,"impliedVol":0.3065,"impliedVolPercentile":0.7341},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2665935968","title":"美国食品药品监督管理局（FDA）加速批准阿斯利康(AZN.O)的Etcamah，用于治疗伴有ESR1突变的晚期乳腺癌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665935968","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665935968?lang=zh_cn&edition=full","pubTime":"2026-09-05 03:47","pubTimestamp":1788551256,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["AZNH","LU0058720904.USD","LU0432979614.USD","159151","BK4568","AZN","LABU","LU2237443549.SGD","LU2237443895.HKD","LU1267930573.SGD","LU2237443465.HKD","LU0029864427.USD","LU2089984988.USD","LU2417539215.USD","BK4007","LU0109394709.USD","LU0708994859.HKD","LU1829250122.USD","LU2236285917.USD","LU2237443382.USD","LU2237443978.SGD","BK4585","BK4588","LU2468319806.SGD","LU2456880835.USD","LU0320765992.SGD","LU0289739699.SGD","LU0128525929.USD","LU0310800379.SGD","IE00B3T34201.USD","LU2462157665.USD","LU2237443622.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664368853","title":"阿斯利康（AZN）抗体偶联药物Enhertu联合疗法获欧盟新适应症批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664368853","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664368853?lang=zh_cn&edition=full","pubTime":"2026-09-01 18:36","pubTimestamp":1788258974,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康 与第一三共联合宣布，其抗体偶联药物Enhertu联合帕妥珠单抗的组合疗法已正式获得欧盟委员会批准，用于一线治疗不可切除或转移性HER2阳性乳腺癌成年患者。这也是Enhertu在短短两个月内于欧盟获得的第二个新适应症批准。随着这一欧盟监管决定的落地，阿斯利康将向第一三共支付1亿美元的里程碑付款。目前，该疗法已在包括美国、中国在内的全球40多个国家和地区获批上市。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/MWM3M2E1ZjMzOTEwODk1MDE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MWM3M2E1ZjMzOTEwODk1MDE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305553","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FSXEmain","LU0432979614.USD","LU2417539215.USD","LU0320765992.SGD","FESXmain","LU1829250122.USD","LU2456880835.USD","LU0289739699.SGD","LU0058720904.USD","LU2237443895.HKD","LU2468319806.SGD","AZN","LU2237443978.SGD","LU0310800379.SGD","LU0029864427.USD","AZNH","BK4568","LU2237443549.SGD","LU0109394709.USD","LU0889565916.HKD","LU1267930573.SGD","LU2237443622.USD","LU0128525929.USD","LU2462157665.USD","LU2089984988.USD","IE00B3T34201.USD","BK4585","BK4007","LU2236285917.USD","LU2237443382.USD","LU0708994859.HKD","BK4588","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167412971","title":"异动解读｜阿斯利康夜盘下跌4.14%，多重管线挫折与竞争压力持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1167412971","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167412971?lang=zh_cn&edition=full","pubTime":"2026-09-01 15:02","pubTimestamp":1788246168,"startTime":"0","endTime":"0","summary":"9月1日，阿斯利康夜盘下跌4.14%，报155.42美元/股，成交额39.88万美元。近期阿斯利康面临多重负面因素叠加。竞争层面，Summit此前公布的依沃西单抗III期试验数据显示疗效优于阿斯利康核心肿瘤药Imfinzi，直接冲击其肿瘤免疫治疗市场地位。技术面上，阿斯利康股价近一个月已累计下跌逾5%，处于横盘偏弱格局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"阿斯利康夜盘下挫，肿瘤管线屡遭挫折","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662671167","title":"疗效碾压阿斯利康(AZN.US)Imfinzi！Summit(SMMT.US)依沃西单抗III期试验数据积极，股价应声大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2662671167","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662671167?lang=zh_cn&edition=full","pubTime":"2026-08-26 20:32","pubTimestamp":1787747523,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","LU0058720904.USD","IE00B3T34201.USD","BK4568","LU2089984988.USD","LU0432979614.USD","LU2462157665.USD","LU0889565916.HKD","SMMT","LU0109394709.USD","AZN","LU2468319806.SGD","LU2237443622.USD","BK4007","LU0029864427.USD","LU0289739699.SGD","LU2237443549.SGD","LU0708994859.HKD","LU1829250122.USD","BK4585","III","LU1267930573.SGD","LU0310800379.SGD","LU2237443382.USD","LU0128525929.USD","BK4588","LU2237443465.HKD","LU2456880835.USD","LU0320765992.SGD","LU2237443978.SGD","AZNH","LU2488822045.USD","LU2237443895.HKD","BK4134","LU2417539215.USD","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662097761","title":"国药控股与阿斯利康启动基药惠民专项合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2662097761","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662097761?lang=zh_cn&edition=full","pubTime":"2026-08-26 11:23","pubTimestamp":1787714595,"startTime":"0","endTime":"0","summary":"南方财经8月26日电，据国药控股消息，近日，国药控股与阿斯利康在上海召开高层战略合作交流会，并正式启动基药惠民专项合作。阿斯利康作为国药控股核心战略合作伙伴，双方在医药流通、创新服务、民生惠民等多个核心领域已形成深度协作。此次项目启动，标志着聚焦国家基药政策落地与基层医疗可及性提升，双方合作已向更深层次、更广领域迈进。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854365220.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854365220.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1829250122.USD","LU0310800379.SGD","LU2237443895.HKD","LU2417539215.USD","BK1515","LU0708994859.HKD","BK4568","LU2236285917.USD","LU0029864427.USD","LU0109394709.USD","LU0889565916.HKD","LU1115378108.SGD","LU1267930573.SGD","LU2237443382.USD","AZNH","LU0289739699.SGD","LU2237443465.HKD","LU2237443622.USD","LU2456880835.USD","BK1197","LU0640798160.USD","BK4588","IE00B3T34201.USD","LU2468319806.SGD","AZN","LU2237443978.SGD","LU0128525929.USD","BK1500","LU2462157665.USD","LU0320765992.SGD","LU0432979614.USD","LU0058720904.USD","LU2237443549.SGD","LU2089984988.USD","BK4585","BK4007","01099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660917282","title":"迪哲医药上半年营收破5亿，已与阿斯利康达成舒沃替尼全球独家许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2660917282","media":"新浪财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660917282?lang=zh_cn&edition=full","pubTime":"2026-08-20 20:55","pubTimestamp":1787230500,"startTime":"0","endTime":"0","summary":"8月20日，迪哲医药发布2026半年报，报告期内，公司实现营业收入5.23亿元，较上年同期增长47%。7月，迪哲医药与阿斯利康签署舒沃替尼的全球独家许可协议，授予阿斯利康在全球范围内独家开发、商业化舒沃替尼的权利。根据协议条款，迪哲医药将获得一次性、不可返还首付款6亿美元，最高达4亿美元的临床开发里程碑款项及最高达5亿美元的销售里程碑款项；此外，还将获得按舒沃替尼全球销售额阶梯式比例的特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-20/doc-ininynce7991209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AZN","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660286748","title":"阿斯利康长效C5补体抑制剂伟立瑞获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660286748","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660286748?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:58","pubTimestamp":1787223480,"startTime":"0","endTime":"0","summary":"南方财经8月20日电，记者获悉，阿斯利康罕见病业务旗下的长效C5补体抑制剂伟立瑞?（英文商品名：Ultomiris?，通用名：瑞利珠单抗注射液），已获得中国国家药品监督管理局（NMPA）批准，用于成人和1月龄及以上儿童阵发性睡眠性血红蛋白尿症（PNH）患者的治疗。PNH是一种慢性、进行性且危及生命的血液系统罕见疾病。该疾病好发于青壮年，77%的PNH患者在20-40岁发病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608203847950261.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608203847950261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","LU2089984988.USD","LU0289739699.SGD","LU2237443465.HKD","BK4588","LU2468319806.SGD","AZNH","LU0432979614.USD","LU0029864427.USD","LU0310800379.SGD","LU2237443978.SGD","LU0058720904.USD","IPOS","AZN","LU2237443382.USD","BK4568","LU0708994859.HKD","LU2237443549.SGD","LU0128525929.USD","LU1267930573.SGD","LU0320765992.SGD","LU2456880835.USD","LU2462157665.USD","LU0109394709.USD","LU2236285917.USD","BK4007","LU2237443895.HKD","LU2417539215.USD","IE00B3T34201.USD","LU0889565916.HKD","LU1829250122.USD","LU2237443622.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660284301","title":"伟立瑞®在华获批用于治疗成人和1月龄及以上儿童阵发性睡眠性血红蛋白尿症（PNH）患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2660284301","media":"美通社","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660284301?lang=zh_cn&edition=full","pubTime":"2026-08-20 18:58","pubTimestamp":1787223480,"startTime":"0","endTime":"0","summary":"此次瑞利珠单抗获批，为成人及儿童PNH患者带来了兼具长效性、稳定性和便利性的治疗选择，可实现快速、完全且持续的终末补体抑制。目前，瑞利珠单抗在中国、美国、欧盟、日本等国家和地区获批用于治疗特定的阵发性睡眠性血红蛋白尿症的成人及儿童患者，并在全球多个国家和地区获批多项适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5030457_ZH30457_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5030457_ZH30457_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["AZN","LU2237443465.HKD","LU2237443549.SGD","LU0109394709.USD","LU2468319806.SGD","LU2462157665.USD","LU0432979614.USD","LU2089984988.USD","IE00B3T34201.USD","LU2237443895.HKD","LU2417539215.USD","LU0128525929.USD","LU0058720904.USD","BK4568","BK4585","LU0289739699.SGD","LU0889565916.HKD","LU2237443622.USD","LU0029864427.USD","LU2236285917.USD","BK4588","LU0708994859.HKD","LU1267930573.SGD","LU0310800379.SGD","LU0320765992.SGD","LU2237443978.SGD","BK4007","AZNH","LU2237443382.USD","LU1829250122.USD","LU2456880835.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660407362","title":"阿斯利康(AZN.US)瑞利珠单抗第3项适应症在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660407362","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660407362?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:50","pubTimestamp":1787215836,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月20日，国家药品监督管理局官网显示，阿斯利康“瑞利珠单抗”国内再获批一项新适应症，用于治疗阵发性睡眠性血红蛋白尿症。瑞利珠单抗于2025年4月首次获批进入中国，用于治疗抗AChR抗体阳性的成人全身型重症肌无力，后又拓展适应症至NMOSD。瑞利珠单抗此次新适应症获批，成为国内第7款、进口第4款PNH治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2237443465.HKD","AZN","LU0310800379.SGD","LU0058720904.USD","LU2462157665.USD","LU2237443382.USD","BK4007","LU0029864427.USD","LU2417539215.USD","LU0109394709.USD","LU1267930573.SGD","BK4568","LU2237443549.SGD","LU2468319806.SGD","AZNH","BK4588","LU0320765992.SGD","LU0128525929.USD","LU2237443978.SGD","LU2237443895.HKD","LU0889565916.HKD","LU2089984988.USD","LU2237443622.USD","LU0432979614.USD","BK4585","LU0289739699.SGD","IE00B3T34201.USD","LU1829250122.USD","LU0708994859.HKD","IPOS","LU2456880835.USD","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157086726","title":"异动解读｜阿斯利康盘中上涨3.1%，多项肺癌III期研究积极结果叠加制药板块集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1157086726","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157086726?lang=zh_cn&edition=full","pubTime":"2026-08-19 22:22","pubTimestamp":1787149321,"startTime":"0","endTime":"0","summary":"8月19日，阿斯利康盘中上涨3.1%，报165.07美元，成交额1.27亿美元。消息面上，公司近日密集释放管线利好。8月17日，阿斯利康与第一三共联合宣布Enhertu单药一线治疗HER2突变非小细胞肺癌的III期DESTINY-Lung04研究取得积极结果，系全球首个在该适应症中单药击败标准疗法的ADC药物。同日，Tagrisso联合赛沃替尼的全球III期SAFFRON研究亦达到PFS和OS双重终点。此外，公司新药特泽利尤单抗已于8月17日宣布在中国正式上市，获批重度哮喘及慢性鼻窦炎伴鼻息肉两项适应症。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660450919","title":"阿斯利康(AZN.US)单抗新药两项适应症在中国上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660450919","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660450919?lang=zh_cn&edition=full","pubTime":"2026-08-18 15:41","pubTimestamp":1787038869,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月17日，阿斯利康宣布，特泽利尤单抗注射液在中国正式上市。2026年3月，特泽利尤单抗基于DIRECTION及WAYPOINT两项3期临床研究的阳性结果，在中国获批两项适应症：用于成人和12岁及以上青少年重度哮喘的维持治疗；本品与鼻用糖皮质激素联合使用，治疗系统性糖皮质激素和/或手术治疗无法充分控制疾病的慢性鼻窦炎伴鼻息肉成人患者。特泽利尤单抗是由阿斯利康与安进合作开发的人源单克隆抗体，可抑制TSLP的活性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481297.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1829250122.USD","LU2237443978.SGD","AZN","LU2462157665.USD","BK4568","BK4585","LU2237443622.USD","BK4588","LU0289739699.SGD","LU0128525929.USD","LU2237443382.USD","LU2237443465.HKD","BK4007","IPOS","LU2236285917.USD","LU1267930573.SGD","LU0889565916.HKD","LU0029864427.USD","IE00B3T34201.USD","LU2089984988.USD","LU2456880835.USD","LU2468319806.SGD","LU0058720904.USD","AZNH","LU0320765992.SGD","LU2237443895.HKD","LU0432979614.USD","LU2417539215.USD","LU0708994859.HKD","LU0109394709.USD","LU0310800379.SGD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660248062","title":"阿斯利康(AZN.US)/第一三共ADC一线治疗肺癌III期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660248062","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660248062?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:44","pubTimestamp":1786970699,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月17日，阿斯利康和第一三共联合宣布Enhertu单药一线治疗非小细胞肺癌的III期DESTINY-Lung04研究取得了高水平的积极结果。结果显示，Enhertu组患者的PFS较标准治疗组实现了统计学显著且临床意义显著的改善。值得一提的是，Enhertu是第一个在III期研究中成功证明单药相较标准治疗作为一线治疗方案能够改善NSCLC患者的PFS的ADC药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0289739699.SGD","LU0320765992.SGD","LU0058720904.USD","AZNH","LU0109394709.USD","LU2468319806.SGD","BK4588","LU0029864427.USD","LU2237443382.USD","III","LU0310800379.SGD","BK4134","BK4007","LU0432979614.USD","LU2417539215.USD","BK4568","LU0128525929.USD","NETL","LU2237443895.HKD","BK4080","LU2237443978.SGD","BK4231","AZN","LU2237443465.HKD","LU2089984988.USD","LU1829250122.USD","LU0889565916.HKD","LU0708994859.HKD","LU2236285917.USD","IE00B3T34201.USD","ADC","LU2462157665.USD","LU1267930573.SGD","LU2456880835.USD","LU2237443622.USD","BK4585","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660147484","title":"阿斯利康终止一项肺癌三期临床试验，称疗效难达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2660147484","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660147484?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:11","pubTimestamp":1786965064,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2237443549.SGD","AZN","LU2462157665.USD","IBBJ","MDTX","LU0889565916.HKD","BK4585","LU0289739699.SGD","LU2089984988.USD","LU0128525929.USD","LU2236285917.USD","LU0109394709.USD","LU2237443895.HKD","BK4568","LU0320765992.SGD","IBBQ","LU2237443382.USD","BK4007","BMED","BK4588","LU2456880835.USD","IE00B3T34201.USD","LU1267930573.SGD","LU2468319806.SGD","LU0029864427.USD","LU1829250122.USD","LU2237443978.SGD","LU2417539215.USD","LU0432979614.USD","LU0058720904.USD","LU2237443465.HKD","LU0708994859.HKD","LU2237443622.USD","PSYK","LU0310800379.SGD","AZNH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660485253","title":"阿斯利康（AZN）再遇重大临床研发挫折 宣布停止肺癌治疗药物Volrustomig三期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2660485253","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660485253?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:52","pubTimestamp":1786956744,"startTime":"0","endTime":"0","summary":"研究结果显示，与现有的标准治疗方案相比，Volrustomig联合化疗未能显著提升晚期肺癌患者的生存率。值得注意的是，这也是阿斯利康在过去一个月内遭遇的第二次重大临床研发挫折。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303852","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2468319806.SGD","LU2237443465.HKD","LU2237443382.USD","LU0058720904.USD","LU2237443978.SGD","AZN","LU2089984988.USD","LU1267930573.SGD","BK4568","LU0109394709.USD","LU0289739699.SGD","LU2237443895.HKD","LU2456880835.USD","LU2462157665.USD","LU2236285917.USD","LU0310800379.SGD","LU2237443622.USD","BK4007","LU0432979614.USD","AZNH","BK4588","LU0128525929.USD","LU2237443549.SGD","BK4585","LU0029864427.USD","IE00B3T34201.USD","LU0889565916.HKD","LU2417539215.USD","LU1829250122.USD","LU0320765992.SGD","LU0708994859.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660362485","title":"阿斯利康（AZN）与日本第一三共联合宣布重磅抗体偶联药物Enhertu®三期临床取得重大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2660362485","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660362485?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:41","pubTimestamp":1786956109,"startTime":"0","endTime":"0","summary":"金吾财讯 | 跨国制药巨头阿斯利康 与日本第一三共联合宣布，其合作开发的重磅抗体偶联药物Enhertu在代号为“DESTINY-Lung04”的全球三期临床试验中取得积极成果。这是全球首个且唯一在HER2突变型非小细胞肺癌一线治疗中战胜标准疗法的HER2靶向药物。据悉，HER2突变型非小细胞肺癌约占非小细胞肺癌患者的2%至4%，常见于较年轻且无吸烟史的女性患者，侵袭性强且易发生脑转移。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/YTM1NDI1NzQzMjY4NQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/YTM1NDI1NzQzMjY4NQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303845","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN","LU0029864427.USD","LU0310800379.SGD","LU2237443382.USD","LU0708994859.HKD","LU1267930573.SGD","LU2456880835.USD","LU2237443465.HKD","LU0128525929.USD","BK4585","LU1829250122.USD","LU2462157665.USD","LU0109394709.USD","LU0889565916.HKD","LU2417539215.USD","LU2089984988.USD","LU0320765992.SGD","IE00B3T34201.USD","LU2236285917.USD","LU2237443895.HKD","LU2237443978.SGD","BK4588","BK4568","BK4007","AZNH","LU0289739699.SGD","LU0432979614.USD","LU2237443622.USD","LU0058720904.USD","LU2468319806.SGD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660072601","title":"阿斯利康(AZN.US)宣布终止其实验性药物volrustomig的临床试验，此前数据显示，该药物似乎无法在肺癌治疗方面","url":"https://stock-news.laohu8.com/highlight/detail?id=2660072601","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660072601?lang=zh_cn&edition=full","pubTime":"2026-08-17 14:48","pubTimestamp":1786949320,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1829250122.USD","LU2237443978.SGD","AZN","PSYK","LU2462157665.USD","BK4568","BMED","BK4585","LU2237443622.USD","IBBQ","BK4588","IBBJ","LU0289739699.SGD","LU0128525929.USD","LU2237443382.USD","LU2237443465.HKD","BK4007","LU2236285917.USD","LU1267930573.SGD","LU0889565916.HKD","LU0029864427.USD","IE00B3T34201.USD","LU2089984988.USD","LU2456880835.USD","LU2468319806.SGD","LU0058720904.USD","AZNH","LU0320765992.SGD","LU2237443895.HKD","LU0432979614.USD","LU2417539215.USD","MDTX","LU0708994859.HKD","LU0109394709.USD","LU0310800379.SGD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660074241","title":"阿斯利康宣布泰适卓在华上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660074241","media":"第一财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660074241?lang=zh_cn&edition=full","pubTime":"2026-08-17 14:24","pubTimestamp":1786947859,"startTime":"0","endTime":"0","summary":"阿斯利康宣布泰适卓在华上市","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843083635.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843083635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0289739699.SGD","LU2417539215.USD","LU2237443465.HKD","LU2237443549.SGD","LU2237443382.USD","BK4588","LU0320765992.SGD","LU2237443978.SGD","LU2236285917.USD","LU0432979614.USD","LU0128525929.USD","LU2456880835.USD","LU0708994859.HKD","LU1829250122.USD","LU0058720904.USD","LU0889565916.HKD","AZN","BK4568","LU0310800379.SGD","LU2089984988.USD","LU2462157665.USD","LU2237443622.USD","LU1267930573.SGD","LU2237443895.HKD","BK4585","IPOS","LU2468319806.SGD","AZNH","IE00B3T34201.USD","LU0109394709.USD","BK4007","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660107356","title":"阿斯利康宣布泰适卓正式在华上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2660107356","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660107356?lang=zh_cn&edition=full","pubTime":"2026-08-17 14:19","pubTimestamp":1786947557,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0310800379.SGD","BK4007","LU2237443622.USD","LU2237443895.HKD","LU2237443465.HKD","LU2456880835.USD","LU2237443549.SGD","LU2417539215.USD","LU2468319806.SGD","LU1829250122.USD","LU2089984988.USD","LU2237443382.USD","LU0432979614.USD","LU0320765992.SGD","BK4585","LU2237443978.SGD","AZNH","LU2462157665.USD","AZN","LU0708994859.HKD","IE00B3T34201.USD","LU0058720904.USD","BK4588","LU0889565916.HKD","IPOS","LU0128525929.USD","LU0109394709.USD","LU0289739699.SGD","LU2236285917.USD","LU0029864427.USD","BK4568","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165315","title":"市场消息：英国首相顾问就布里斯托尔并购案联系阿斯利康。","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165315","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659165315?lang=zh_cn&edition=full","pubTime":"2026-08-13 23:13","pubTimestamp":1786633991,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1829250122.USD","LU2237443978.SGD","AZN","LU2462157665.USD","BK4568","BK4585","LU2237443622.USD","BK4588","LU0289739699.SGD","LU0128525929.USD","LU2237443382.USD","LU2237443465.HKD","BK4007","LU2236285917.USD","LU1267930573.SGD","LU0889565916.HKD","LU0029864427.USD","IE00B3T34201.USD","LU2089984988.USD","LU2456880835.USD","LU2468319806.SGD","LU0058720904.USD","AZNH","LU0320765992.SGD","LU2237443895.HKD","LU0432979614.USD","LU2417539215.USD","LU0708994859.HKD","LU0109394709.USD","LU0310800379.SGD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659860121","title":"第一三共/阿斯利康(AZN.US)重磅ADC药物“德曲妥珠单抗”又一项新适应症在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2659860121","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659860121?lang=zh_cn&edition=full","pubTime":"2026-08-13 07:21","pubTimestamp":1786576889,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月12日，第一三共宣布，其与阿斯利康合作开发的重磅ADC药物“德曲妥珠单抗”一项新适应症获批上市，适应症为联合帕妥珠单抗用于不可切除或转移性HER2阳性成人乳腺癌患者的一线治疗。德曲妥珠单抗(DS-8201，商品名：优赫得®/Enhertu)是一款靶向HER2的ADC药物，由第一三共开发，并与阿斯利康在全球范围内共同开发和商业化。该药由HER2靶向抗体、可裂解四肽连接子和拓扑异构酶I抑制剂DXd(依喜替康衍生物)组成，DAR约为8。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0029864427.USD","BK4007","LU2237443895.HKD","ADC","LU2237443382.USD","LU0128525929.USD","LU2237443978.SGD","IE00B3T34201.USD","LU0432979614.USD","LU0310800379.SGD","LU2089984988.USD","BK4568","LU0058720904.USD","LU2237443622.USD","BK4231","LU2417539215.USD","LU2456880835.USD","LU2237443465.HKD","LU2237443549.SGD","BK4588","BK4080","IPOS","LU2462157665.USD","LU2236285917.USD","LU0889565916.HKD","NETL","LU2468319806.SGD","LU0109394709.USD","BK4585","AZN","LU0708994859.HKD","LU1829250122.USD","LU1267930573.SGD","LU0320765992.SGD","AZNH","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0074},{"period":"3month","weight":-0.125},{"period":"6month","weight":-0.1623},{"period":"1year","weight":-0.0053},{"period":"ytd","weight":-0.1151}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.012868},{"month":3,"riseRate":0.545455,"avgChangeRate":0.025511},{"month":4,"riseRate":0.636364,"avgChangeRate":0.028791},{"month":5,"riseRate":0.515152,"avgChangeRate":0.008212},{"month":6,"riseRate":0.470588,"avgChangeRate":0.018421},{"month":7,"riseRate":0.588235,"avgChangeRate":-0.005538},{"month":8,"riseRate":0.470588,"avgChangeRate":0.003346},{"month":9,"riseRate":0.558824,"avgChangeRate":0.001299},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NYSE","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}